Compare IGIC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | MRVI |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2020 |
| Metric | IGIC | MRVI |
|---|---|---|
| Price | $24.50 | $6.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $31.00 | $7.83 |
| AVG Volume (30 Days) | 90.9K | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $4.98 | $14.01 |
| Revenue Next Year | $2.89 | $6.20 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.82 | $2.55 |
| 52 Week High | $29.59 | $9.42 |
| Indicator | IGIC | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 40.52 |
| Support Level | $24.34 | $6.49 |
| Resistance Level | $26.04 | $7.60 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 46.30 | 0.48 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.